Similarly, in the KEYNOTE-040 phase III clinical trial, an advantage in overall survival was demonstrated with pembrolizumab, particularly in the subset of patients with a PD-L1 expression of ≥50% on tumor cells (median overall survival 11.6 months vs. 7.9 months; HR 0.54) [70,71]. The gene discussed is CD274; the disease is neoplasm.